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SUMMARY 
It has been suggested that elevated luteal phase prolactin (PRL) levels may have an important 
role in causing some of the symptoms of the premenstrual tension syndrome (PMTS). Thirty-seven 
women suffering from severe premenstrual dysphoria were selected for this study. Single morning 
and afternoon serum PRL evaluations were performed during the follicular (day 9) and late luteal 
(day 26) phases of the menstrual cycle. PRL was measured by an established double antibody 
radioimmunoassay technique. 
All mean PRL values were within the normal range. Only afternoon mean PRL levels showed a 
tendency for a premenstrual increase. The significance of this statistical finding is unclear, since 
one-third of the subjects showed a decrease in premenstrual PRL levels. Twenty-four hour PRL 
secretory profiles recorded on clays 9 and 26 in two women with extremely severe PMTS and in two 
asymptomatic matched control subjects also failed to show a significant correlation between PRL 
levels and PMTS. 
Thirty subjects participated in a treatment trial using bromocriptine. A marked rebound 
hyperprolactinemia was observed in a subgroup of women nine days after cessation of 
bromocriptine. This was associated with no detectable effec~ on mood, behaviour, or menstrual 
regularity. Thus, our data fail to show any specific relationship between PRL and PMTS. 
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INTRODUCTION 
VARIOUS forms of hormonal imbalance have been claimed to be etiologically important in 
the premenstrual tension syndrome (PMTS). Horrobin 0973) first proposed a major role 
for hyperprolactinemia and later reviews have considered the evidence in support of this 
association (Steiner & Carroll, 1977; Carroll & Steiner, 1978). There are essentially three 
groups of findings: 
(1) Prolactin (PRL) levels tend to be higher in the luteal phase than the follicular phase 
of the menstrual cycle (Franchimont et  al., 1976; Vekemans et  al., 1977; Bohnet et  ai. ,  
1979). Serum PRL levels also remain elevated until the onset of menses, unlike estrogen, 
progesterone, renin, angiotensin, and aldosterone, whose levels begin to fall one week 
before menses (Frantz, 1979). This late luteal hyperprolactinemia coincides with the 
timing of PMTS. 
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(2) PRL levels are elevated in some women with manifestations of PMTS (Halbreich et  
al., 1976; Horrobin et  al., 1976). However, another study, published after the completion 
of the work presented herein, showed no differences between mean luteal phase PRL 
levels of women suffering from PMTS compared to those of controls (Backstrom & 
Aakvaag, 1981). 
(3) Symptoms of PMTS have been claimed to be markedly ameliorated by 
bromocriptine, a PRL suppressant (Benedek-Jaszmann & Hearn-Sturtevant, 1976). 
However, other investigators have failed to replicate these findings (Andersen et  al., 1977; 
Ghose & Coppen, 1977; Andersch et  al., 1978; Graham et  al., 1978). 
The present study was designed to further investigate the postulated role of PRL in 
PMTS. 
METHODS 
Subjects for this study were 37 adult women (ages 22 -  42 years) who complained of a severe dysphoric 
syndrome in the premenstruum, but who showed no evidence of emotional disorder at other times. Their 
premenstrual dysphoric symptoms bad been present for at least six consecutive menstrual cycles. They showed 
no abnormality on physical examination, and all had normal routine laboratory values. Their six previous 
menstrual cycles had been regular, and they were completely drug-free for at least four weeks before entering the 
study. 
After giving informed consent, all subjects were evaluated twice during the menstrual cycle. This occurred 
during a follicular phase visit on day 9 (day I = onset of menses) and a lutcai phase visit, on or around day 26, 
but always two to six days premenstrual, counting back from the first day of menses. The clinical severity of the 
symptoms and the on/off  nature of the phenomena were assessed by several observer and self-rating scales 
(Haskett et al., 1980; Steiner et al., 1980). Single PRL levels were obtained from all 37 womea at 1600 hr during 
both the follicular (day 9) and late luteal phases (day 26). In 21 of the subjects a 1000 hr PRL sample alsowas 
taken. 
In addition, two subjects with extremely severe PMTS and two asymptomatic healthy female controls 
participated in a study of 24-hr PRL secretion patterns. These women were admitted to the Clinical Research 
Center on days 9 and 26 of their menstrual cycles. The follicular phase (day 9) studies preceded the iutcal phase 
(day 26) studies in all subjects. Blood samples were collected every 30 min for 26 hr from an indwelling catheter 
in the antecubital vein. Severity of symptoms was established by using the Menstrual Distress Questionnaire; 
Form-T (MDQ-T) (Moos, 1969). The MDQ is a 47 symptom scale with a score of I to 6 [i.e. 1 = no symptoms at 
all (minimum total score = 47); 6 = extremely disabling (maximum total score = 282)]. The Form-T (Today) is 
rated according to the presence of each symptom on the day of completing the scale. 
Thirty subjects participated in a treatment trial of bromocriptine (CB-IS4) and received doses ranging from 
2.5 to 7.5 mg daily. The trial was a double-blind placebo controlled design. Subjects received medication or 
placebo from day 10 until the onset of menses for three consecutive cycles. Details of the clinical responses to 
this treatment are reported separately (Steiner et al., 1983). Serum PRL levels were estimated in !0 women taking 
2.5, 5.0 or 7.5 mg bromocriptine daily, The blood samples were drawn between 0900 and 1200 hr on days 9 and 
26 of a pretreatment cycle (cycle 0) and for each of the three cycles of the trial (cycles 1 - 3). 
Serum PRL was measured by an established double antibody radioimmunoassay technique (Sinha et al., 
1973), with intra-assay variability of 8.9070, inter-assay variability of 13.8070, and sensitivity of 0.1 ng/tube. 
Human PRL (hPRL, AFP 1562-C) for iodination and standard was kindly provided by Dr. Albert F. Parlow. 
lodination was performed according to the glucose oxidase - lactoperoxidase method (Tower et al., 1977), and 
the suitability of the '251-PRL was verified by the talc - resin - TCA technique (Tower et al., 1978). Anti-hPRL 
(AFP-I) was supplied by the National Pituitary Agency. Values are reported as ng/ml of hPRL AFP 1562.C 
(Hays & Rubin, 1979). The data were analyzed by two-tailed t-test and analysis of variance with repeated 
measures. 
RESULTS 
The values obtained for the serum PRL estimations during the two phases of  the 
menstrual cycle are shown in Fig. 1. All mean values were within the normal range 
( 1 2 . 8 -  17.3 ng/ml).  There was no significant difference between morning ( 1 ~  hr)and 
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FIG. 1. Comparison of serum PRL levels (ng/ml) during the follicular and late luteal phases of the menstrual 
cycle in women with severe PMTS. Blood samples were obtained at 1600 hr in 37 subjects; 21 subjects also had 
blood samples taken at 1000 hr (*p < 0.05). 
afternoon (1600 hr) samples during either phase of the cycle. No significant difference was 
found between follicular and late luteal mean PRL levels at 1000 hr. There was, however, 
a significant increase in mean PRL levels at 1600 hr from follicular to late luteal phase 
(p < 0.05; two-tailed t-test). Although statistically significant, the implications of this 
finding are unclear. One-third of the subjects (12 of  the 37 women sampled at 1600 hr and 
six of the 21 sampled at 1000 hr) showed lower PRL levels during the late luteal 
(premenstrual) phase than during the follicular phase. There was no obvious clinical 
difference between women who had increased and those who had decreased late luteal 
phase PRL levels. 
Mean serum PRL levels from the two women with severe PMTS who participated in the 
24-hour catheter studies are shown in Table I. In one subject (No. 1), her mean PRL level 
in the late luteal (premenstrual) phase, recorded when she was severely affected by 
symptoms of PMTS (with an extremely high MDQ-T total score of 194), was higher than 
her mean PRL level in the follicular phase. A much smaller change was seen in the other 
subject (No. 2), who also was markedly symptomatic, with a very high MDQ-T total score 
of 171. Table I also shows the mean PRL levels from the asymptomatic control subjects. 
It is notable that, although both subjects denied any features of PMTS, also evidenced by 
their minimal scores on the MDQ-T, subject No. 4 had a marked elevation of her mean 
TABLE I. TWENTY-FOUR HOUR MEAN SERUM PRL LEVELS AND MENSTRUAL DISTRESS QUESTIONNAIRe SCORES IN TWO 
WOMEN WITH SEVERE P M T S  AND IN TWO CONTROL SUBJECTS 
Serum PRL (ng/ml) 
Subject Phase (mean ± S.E.M.) MDQ-T total score 
PMTS No. I Follicular I0.5 ± 0.6 76 
Late luteal 25.3 _+ I.I 194 
PMTS No. 2 Follicular 8.0 ± 0.4 63 
Late luteal I 1.0 ± 0.7 171 
Control No. 3 Follicular 19.1 ± 0.7 48 
Late luteal 20.4 ± 0.6 55 
Control No. 4 Follicular 29.8 ± 0.8 74 
Late luteal 49.5 ± 1.0 59 
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PRL level in the late luteal (premenstrual) phase. This woman stated that her menses 
appeared each month with absolutely no preceding emotional or somatic changes, and no 
behavioural aspects of PMTS were apparent during the study. 
Table II shows the serum PRL levels for 10 subjects measured during the follicular and 
late luteal (premenstrual) phases of four menstrual cycles, a pretreatment cycle (cycle 0) 
and three cycles of treatment (cycles l - 3 ) .  Subjects were taking bromocriptine when 
sampled on day 26 of cycles l - 3, and all medication was discontinued on day l of the 
following cycles. As shown, bromocriptine suppressed PRL on day 26, but the mean 
serum PRL levels on day 9 were significantly elevated (p < 0.004; ANOVA, repeated 
measures). Despite this marked "rebound" hyperprolactinemia following the cessation of 
bromocriptine, all subjects remained free of symptoms, with no observable effects on 
mood, behaviour or menstrual regularity. 
DISCUSSION 
Our data failed to show any specific relationship between serum PRL levels and PMTS. 
Even though there was a slight premenstrual increase of PRL, neither the PRL 
measurements from single blood samples nor the 24-hr PRL secretion profiles support the 
hypothesis that PMTS is associated with an elevation in serum PRL levels. As mentioned, 
similar results have been reported by Backstrom & Aakvaag (1981). 
Some very high PRL levels were recorded in this study, at times when women reported 
being completely free of symptoms. In particular, the "rebound" hyperprolactinemia 
which followed the cessation of bromocriptine coincided with an interval of marked relief 
from PMTS symptoms. The lack of emotional or behavioural changes during a 
" rebound" hyperprolactinemia has not been reported before, to our knowledge. 
The assessment of PRL levels in patients with PMTS is particularly difficult. The 
secretion of  PRL is pulsatile, and serum levels fluctuate with repeated measures over 
intervals of a few minutes. PRL also is released after emotional or physical stress (Noel et  
ai., 1972). We tried to minimize this effect in our 24-hr catheter studies by sampling all 
subjects during the follicular phase prior to the late luteal (premenstrual) sampling. The 
PRL levels obtained from single blood samples should, nevertheless, be interpreted 
cautiously. 
The 24-hr PRL profiles from the subjects in this study showed great variation and no 
obvious relationship to PMTS or menstrual cycle phase. One other study of 24-hr PRL 
profiles in an asymptomatic subject, measuring episodic release and diurnal variation, 
showed an increase in nocturnal PRL release at midcycle or the time of ovulation (Ehara 
et  al., 1973). Other stimuli of PRL secretion include meals and changes in ambient 
temperature (Quigley et  ai., 1981; Mills & Robertshaw, 1981). Previous studies have not 
controlled for these variables, and it is now obvious that future studies should. 
Finally, even if PRL secretion can be shown to be associated with the clinical features of 
PMTS, this hormone may be serving as an endocrine reflection of central 
neurotransmitter activity rather than as a direct etiological agent for these symptoms. 
Many of the transmitters which influence the activity of the hypothalamic-pi tu i tary-  
gonadal (HPG) axis during the normal menstrual cycle are also believed to alter the 
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s y m p t o m s  m a k e s  i t  a r e a s o n a b l e  h y p o t h e s i s  t h a t  t h e y  a r e  r e l a t e d  t o  t h e  cycl ica l  
n e u r o e n d o c r i n e  c h a n g e s  in t h e  H P G  axis ,  so t h a t  it is p o s s i b l e  t h a t  c h a n g e s  in  P R L ,  
e s t r o g e n s  o r  p r o g e s t e r o n e ,  w h i c h  a r e  a n  i m p o r t a n t  p a r t  o f  t h e  m e n s t r u a l  cycle ,  h a v e  a n  
i n d i r e c t ,  s t i l l  u n c l e a r  r e l a t i o n s h i p  to  P M T S .  
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